BioCryst updates cost estimate for closing Alabama discovery facility
The company now pegs one-time severance costs at $6.2 to $7.5 million after saying in June it could not yet quantify the expense.
BioCryst Pharmaceuticals filed an amended Current Report on Form 8-K/A dated August 4, 2026, updating financial details tied to a facility closure it first disclosed in June. The amendment addresses Item 2.05 of the original filing and supplements disclosure the company had made in an 8-K filed on June 29, 20261.
On June 29, 2026, BioCryst announced plans to shut down its internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama, describing the move as part of a broader effort to focus resources on its rare disease pipeline1. At that time, the company said it could not yet produce a reliable cost estimate for the plan1.
In this amended filing, BioCryst provided that estimate. It now expects to incur $6.2 million to $7.5 million in one-time costs tied to staff severance and termination benefits, with roughly $5.3 million to $6.6 million of that expected to be paid in cash1.
The company noted that additional costs remain unresolved. It anticipates further expenses from closing the facility itself, including possible contract and lease termination charges or asset impairments, but said its review of those costs is still underway and it cannot yet estimate their size or cash impact1. BioCryst said it will file another amended 8-K or other periodic report once it can provide that estimate1.
The filing was signed by Chief Legal Officer Alane Barnes.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.